Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Two Formulations of Eszopiclone 3.0 mg
NCT05349396Phase 1Completed
- Sponsor
- Laboratorios Andromaco S.A.
- Start
- Apr 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eszopiclone in Insomnia (3 arms), sponsored by Laboratorios Andromaco S.A. Primary endpoints: Area under the plasma concentration-time curve from 0 to 24 hours, Area under the plasma concentration-time curve from time zero to time t at 24 hours and 2 more. Started Apr 2022; status: completed.
02
Drugs
eszopiclone
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05349396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349396.